<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="233">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00960479</url>
  </required_header>
  <id_info>
    <org_study_id>P1BH00001</org_study_id>
    <nct_id>NCT00960479</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions</brief_title>
  <official_title>A Relative Bioavailability Study of Ribavirin (Geneva Pharmaceutical Technology Corporation, N.J., U.S.A.) 200 Capsules and Rebetol (Schering Corporation, N.J., U.S.A.) 200 mg Capsules in Females Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the relative bioavailability of Ribavirin 200
      capsules and Rebetol 200 mg capsules in females under fasting conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">February 2001</completion_date>
  <primary_completion_date type="Actual">February 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Bioequivalence based on AUC and Cmax</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No clinically significant abnormal finding on physical exam, medical history, or
             clinical laboratory results on screening.

        Exclusion Criteria:

          -  Positive test results for HIV or hepatitis B or C.

          -  Treatment for drug or alcohol dependence.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piyush Patel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allied Clinical Research</affiliation>
  </overall_official>
  <verification_date>August 2009</verification_date>
  <lastchanged_date>August 14, 2009</lastchanged_date>
  <firstreceived_date>August 13, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Eric Mittleberg, Ph.D, VP of Product Development</name_title>
    <organization>Sandoz Inc.</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
